Phase 1 clinical trial in Japan assessing S-892216 in healthy adults
Latest Information Update: 24 May 2023
Price :
$35 *
At a glance
- Drugs S 892216 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- 24 May 2023 New trial record
- 17 May 2023 According to Shionogi media release, the first dose in this Phase 1 clinical trial was administered successfully and no safety concerns have been identified.